Akero Therapeutics says mid-stage trials on drug for fatty liver disease positive
HQ Team March 4, 2024: US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team March 4, 2024: US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary.
New drug can help activate liver regeneration and repair in end-stage liver disease
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com